Brief: Wave Life Sciences Announces Positive Interim Data From Forward-53 Clinical Trial Evaluating Wve-N531 In Boys With Duchenne Muscular Dystrophy Amenable To Exon 53 Skipping
24/09/2024 12:32
Sept 24 (Reuters) - WAVE Life Sciences Ltd WVE.O :
* WAVE LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM
FORWARD-53 CLINICAL TRIAL EVALUATING WVE-N531 IN BOYS WITH
DUCHENNE MUSCULAR DYSTROPHY AMENABLE TO EXON 53 SKIPPING
* WAVE LIFE SCIENCES LTD - WVE-N531 SAFE AND WELL TOLERATED
WITH
NO SERIOUS ADVERSE EVENTS
* WAVE LIFE SCIENCES LTD - EXPECTS FEEDBACK ON ACCELERATED
APPROVAL PATHWAY IN 1Q 2025
Source text for Eikon: ID:nGNX1bzvPd
Further company coverage: WVE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Wave Life Sciences
See all newsWave Life Sciences Ltd Reports Results For The Quarter Ended June 30: Earnings Summary
Wave Life Sciences Ltd Expected To Post A Loss Of 31 Cents A Share: Earnings Preview
Wave Life Sciences Q1 revenue jumps, beats analyst estimates
Brief: Wave Life Sciences Announces Hearing On Proposed Redomiciliation To The United States
Brief: Wave Life Sciences Announces Proposed Redomiciliation To The United States